Eisai Submits Aricept VaD sNDA; Study Criteria Endorsed By Committee
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai/Pfizer are looking to expand Aricept’s approved indications to include vascular dementia based on two studies that enrolled patients using NINDS-AIREN diagnosis criteria.